Plain-English translation of NCT04657068 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer medication called , which works by targeting a specific protein involved in cancer cell DNA repair. The medication is being tested both on its own and combined with other chemotherapy drugs in people with advanced cancers. Researchers want to find the right doses, understand how the medication works in the body, and see whether it can help shrink tumors.
Many cancers have defects in their DNA repair systems, which makes them potentially vulnerable to this type of treatment. This trial exists to determine whether this medication can safely and effectively treat cancers that have these specific vulnerabilities.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth, either as a single agent or combined with other chemotherapy, in repeated 21-day treatment cycles. Your participation would include regular clinic visits for blood tests, imaging scans to measure your tumors, and assessments of how you're tolerating the treatment. The study will evaluate your safety, how the medication moves through your body, and whether your cancer responds to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States